- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02338271
Autologous Adipose Derived Stem Cell Therapy for Intervertebral Disc Degeneration
Safety and Efficacy Study of Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration
Subject: 10 patients
: Chronic low back pain patients with lumbar intervertebral disc degeneration
Investigational Product
: Autologous adipose derived mesenchymal stem cells plus hyaluronic acid derivatives (Tissuefill)
Time frame
- 1 year
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose of the Clinical Study
: To transplant autologous adipose derived mesenchymal stem cells with hyaluronic acid to patients with chronic low back pain caused by a degenerative lumbar disc to examine the procedure's safety and efficacy.
Phases and Design of the Clinical Study
: This clinical study is a I/IIa phase single-group, open, investigator initiated trial.
- Investigational Product : Autologous adipose derived mesenchymal stem cells separated from the subject (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial).
The investigational product mixed with 1 mL of the concomitant drug Tissuefill (hyaluronic acid derivatives, Cha Meditech Co., Ltd.).
4. Inclusion Criteria
- Males and female subjects aged 18 or over and less than 70.
- Subjects who have experienced pain in the lower back or buttocks who have failed to respond to conservative therapies performed for a period of 3 months or longer.
- Oswestry Disability Index of 30 % or higher.
- Visual Analogue Scale of 4 or higher.
- Subjects who have received a Magnetic Resonance Imaging (hereinafter referred to as MRI) assessment of grades 3 to 4 for Lumbar 1 - Sacral 1, according to the Pfirrmann grading system.
- Subjects who are assessed to have a similar degree of pain as usual when a discogram is performed on the degenerative lumbar disc(s) identified by MRI, having one or two discs that cause the concordant pain.
- Subjects who have signed the informed consent form for stem cell transplantation therapy.
5. Exclusion Criteria
- Subjects with severe lumbar stenosis or herniated nucleus pulposus in the lumbar exhibiting symptoms of nerve compression and requiring surgery.
- Subjects with spinal instability, spondylitis, or vertebral fractures
- Patients with severe intervertebral disc degeneration that has resulted in a reduction of the disc height by ½ or more.
- Subjects with severe osteoporosis (with an average T-score of -2.5 or below in the lumbar bone density test)
- Patients who have received intra-discal procedures such as stem cell therapy or the injection of steroids into the disc or surgery such as discectomy on the disc on which the cell transplantation is planned to be performed.
- Patients who have received a lumbar epidural steroid injection within a week prior to the cells transplantation.
- Subjects who are hypersensitive to sodium hyaluronate.
- Pregnant or breastfeeding women
- Female patients with the possibility of pregnancy during the period of the clinical study who are not using a medically acceptable method of contraception.
- Subjects with mental illness or a drug or alcohol addiction or subjects who are incapable of understanding the purpose and method of this clinical study.
- Subjects who have participated in another clinical study in the 30 days prior to this study.
- Subjects with a severe medical disease (hypertension unresponsive to drug treatment, diabetes unresponsive to drug treatment, hepatocirrhosis, renal failure, tumor) that can affect the outcome of this clinical study.
- Subjects with any other clinically significant findings that renders the subject unsuitable for the clinical study, as judged by the investigator responsible for the clinical study.
6. Dosage and Administration
: The autologous adipose derived mesenchymal stem cell as the investigational product (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill 1mL/syringe are supplied to the operating room. The investigational product and the Tissuefill (hyaluronic acid derivatives) are mixed and placed in a 22 G syringe. A single dosage of 2ⅹ10^7 autologous adipose derived mesenchymal stem cells per person is administered on 5 subjects, and a single dosage of 4ⅹ10^7 cells per person is administered on 5 subjects, injected into the center of the nucleus pulposus.
7. Primary Endpoint: Evaluation of Safety and Tolerability The transplantation will be considered to be safe and tolerable, in the absence of the following types of counterevidence.
- Adverse events of grade 3 (NCI grading system) or above related to the cell products/ any evidence that the cells were contaminated by pollutants / any evidence that the cells exhibit tumorigenic potential
8. Secondary Endpoint
- Change in the T2 MRI signal intensity of the nucleus pulposus in autologous adipose derived mesenchymal stem cells at 6 and 12 months after the transplantation compared to before the transplantation
- Change in the VAS at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
- Change in the ODI at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
- Change in the Short Form (SF)-36 at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
- Assessment of the overall improvement in the Disc Height Index (hereinafter referred to as DHI) at 6 and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Inbo Han, MD, PhD
- Phone Number: +82-31-780-5688
- Email: hanib@cha.ac.kr
Study Contact Backup
- Name: Kyunghoon Min, MD
- Phone Number: +82-31-780-5688
- Email: minkh@chamc.co.kr
Study Locations
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-712
- Recruiting
- CHA University, CHA Bundang Medical Center
-
Contact:
- Inbo Han, MD, PhD
- Phone Number: +82-31-780-5688
- Email: hanib@cha.ac.kr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who have experienced pain in the lower back or buttocks who have failed to respond to conservative therapies performed for a period of 3 months or longer.
- Oswestry Disability Index of 30% or higher.
- Visual Analogue Scale of 4 or higher.
- Subjects who have received a Magnetic Resonance Imaging (hereinafter referred to as MRI) assessment of grades 3 to 4 for Lumbar 1 - Sacral 1, according to the Pfirrmann grading system.
- Subjects who are assessed to have a similar degree of pain as usual when a discogram is performed on the degenerative lumbar disc(s) identified by MRI, having one or two discs that cause the pain.
- Subjects who have signed the informed consent form for stem cell transplantation therapy.
Exclusion Criteria:
- Subjects with severe lumbar stenosis or herniated nucleus pulposus in the lumbar exhibiting symptoms of nerve compression and requiring surgery.
- Subjects with spinal instability, spondylitis, or vertebral fractures
- Patients with severe intervertebral disc degeneration that has resulted in a reduction of the disc height by ½ or more.
- Subjects with severe osteoporosis (with an average T-score of -2.5 or below in the lumbar bone density test)
- Patients who have received intra-discal procedures such as stem cell therapy or the injection of steroids into the disc or surgery such as discectomy on the disc on which the cell transplantation is planned to be performed.
- Patients who have received a lumbar epidural steroid injection within a week prior to the cells transplantation.
- Subjects who are hypersensitive to sodium hyaluronate.
- Pregnant or breastfeeding women
Female patients with the possibility of pregnancy during the period of the clinical study who are not using a medically acceptable method of contraception.
* Medically acceptable methods of contraception: condoms, an oral contraceptive administered continually for at least 3 months, an implantable contraceptive surgically inserted 3 months prior to the clinical study, injected or inserted contraceptives, an intrauterine contraceptive device, etc.
- Subjects with mental illness or a drug or alcohol addiction or subjects who are incapable of understanding the purpose and method of this clinical study.
- Subjects who have participated in another clinical study in the 30 days prior to this study.
- Subjects with a severe medical disease (hypertension unresponsive to drug treatment, diabetes unresponsive to drug treatment, hepatocirrhosis, renal failure, tumor) that can affect the outcome of this clinical study.
- Subjects with any other clinically significant findings that renders the subject unsuitable for the clinical study, as judged by the investigator responsible for the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: a single, open clinical trial
a single-group, open, investigator-initiated clinical study : autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe |
autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Safety and Tolerability (Adverse events)
Time Frame: 12months
|
The transplantation will be considered to be safe and tolerable, in the absence of the following types of counter evidence. - Adverse events of grade 3 (NCI grading system) or above related to the cell products/ any evidence that the cells were contaminated by pollutants / any evidence that the cells exhibit tumorigenic potential. Adverse events will be reported at 1, 3, 6, 9, and 12 months |
12months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the T2 MRI signal intensity of the nucleus pulposus
Time Frame: 12months
|
Change in the T2 MRI signal intensity of the nucleus pulposus in autologous adipose derived mesenchymal stem cells at 6 and 12 months after the transplantation compared to before the transplantation
|
12months
|
Overall improvement in the Disc Height Index
Time Frame: 12months
|
Assessment of the overall improvement in the Disc Height Index at 6 and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
|
12months
|
improvement in Visual Analogue Scale (VAS)
Time Frame: 12 months
|
Change in the VAS at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
|
12 months
|
improvement in Oswestry Disability Index (ODI)
Time Frame: 12 months
|
Change in the ODI at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
|
12 months
|
improvement in Short Form-36
Time Frame: 12 months
|
Change in the Short Form (SF)-36 at 1, 3, 6, 9, and 12 months after the transplantation of autologous adipose derived mesenchymal stem cells, compared to before the transplantation
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Inbo Han, MD, PhD, CHA Bundang Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADMSC-DD-Han
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
University School of Physical Education in WroclawCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, PosturalPoland
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
University of ParmaKing's College London; Helmholtz Zentrum München; GENOS; Ip Research Consulting... and other collaboratorsUnknownChronic Low Back Pain | Acute Low Back PainUnited States, Australia, Belgium, Croatia, Italy, United Kingdom
-
Ache Laboratorios Farmaceuticos S.A.Unknown
-
Palmer College of ChiropracticDepartment of Health and Human ServicesCompletedChronic Low Back Pain | Subacute Low Back PainUnited States
-
Universität Duisburg-EssenSiemens-BetriebskrankenkasseCompletedChronic Low Back Pain | Recurrent Low Back Pain
-
Karolinska InstitutetCompletedChronic Low Back Pain | Recurrent Low Back Pain | Persistent Low Back PainSweden
-
Apsen Farmaceutica S.A.CompletedLow Back Pain | Low Back Pain, Mechanical | Acute Low Back PainBrazil
Clinical Trials on autologous adipose derived mesenchymal stem cell
-
Celal Bayar UniversityThe Scientific and Technological Research Council of Turkey; Acıbadem LabcellCompletedSkin Diseases | Immune System Diseases | Autoimmune Diseases | UrticariaTurkey
-
Mohamad BydonCompletedParalysis | Spinal Cord InjuriesUnited States
-
The Foundation for Orthopaedics and Regenerative...SuspendedSpinal Cord InjuriesGreece
-
National Yang Ming UniversityCompletedThe Sequelae Caused by Severe Brain InjuryTaiwan
-
The Foundation for Orthopaedics and Regenerative...Suspended
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityCompleted
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedDiabetes | Critical Limb Ischemia (CLI)Spain
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
Anterogen Co., Ltd.TerminatedPerianal Fistula | Primary; ComplexKorea, Republic of
-
Anterogen Co., Ltd.TerminatedComplex Perianal FistulaKorea, Republic of